Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care giant Abbott Labs (NYSE: ABT) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Abbott's business and see what CAPS investors are saying about the stock right now.

Abbott facts

Headquarters (founded)

Abbott Park, Ill. (1888)

Market Cap

$74.6 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$33.99 billion

Management

CEO Miles White (since 1999)

CFO Thomas Freyman (since 2001)

Return on Equity (average, past 3 years)

25.2%

Cash/Debt

$3.85 billion / $18.72 billion

Dividend Yield

3.7%

Competitors

Johnson & Johnson (NYSE: JNJ)

Merck (NYSE: MRK)

Pfizer (NYSE: PFE)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 98% of the 6,178 members who have rated Abbott believe the stock will outperform the S&P 500 going forward. These bulls include All-Star boxxer55, who is ranked in the top 10% of our community, and SlyMiah.

Just last week , boxxer55 tapped Abbott as a healthy income opportunity: "Low P/E, significant bottom line income growth projections, good dividend yield and dividend coverage. There is a lot to like about this stock at this price."

Abbott's strong roster of patent-protected drugs and attractive new pipeline continue to support its five-star CAPS status. Over the next five years, Abbott is even expected to grow its bottom line at a faster pace (9.6% per annum) than rivals Johnson & Johnson (6.1%), Merck, and Pfizer, as well as foreign foes such as GlaxoSmithKline (NYSE: GSK) (3%) and Novartis (NYSE: NVS) (5.2%).

CAPS member SlyMiah elaborates on the bargain opportunity:

Abbott Stock has been around so long, I don't think people realize just how good it is. Abbott has been around since 1888 and over that time, they have been great about adapting an morphing their organization as time changed. ... The stock price hasn't gone up of late, I believe because of uncertainty last year with healthcare reform and concern over what comes after Humira. I'm not swayed by these concerns because if there is anything Abbott does well, it's prepare and adapt.

What do you think about Abbott, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Pfizer is a Motley Fool Inside Value pick. Johnson & Johnson is an Income Investor choice, and Motley Fool Options has recommended a diagonal call position on it. Novartis is a Global Gains choice. The Fool owns shares of Johnson & Johnson. Motley Fool Alpha owns shares of Johnson & Johnson and Abbott. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.